The data suggest that the silencing of Runx2 could represent a novel strategy to impede the osteoblastic phenotypic shift of VIC and the ensuing progress of CAVD. The gene discussed is RUNX2; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.